Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.53 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.48 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.45 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.44 |
| ▸ | SHH | Q15465 | 1/20 | 0.44 |
| ▸ | MSTN | O14793 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379999 | 0.97 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| Endothelin SCHEMBL29403065 | 0.94 | RXFP1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| Endothelin SCHEMBL21644373 | 0.94 | RXFP1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL26929028 | 0.94 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29403556 | 0.94 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29484633 | 0.93 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29921568 | 0.90 | KCNMA1 (0.54) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29661263 | 0.88 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP1SSTR2SSTR5 | |
| SCHEMBL21412615 | 0.81 | IL23R (0.58) | KCNMA1KCNMB4RXFP3SSTR2SSTR5 | |
| SCHEMBL21412610 | 0.81 | IL23R (0.58) | KCNMA1KCNMB4RXFP3SSTR2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 876 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4718076-A2 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN | B.R.A.H.M.S GmbH (DE) | 2026-04-01 | — | — | EP | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3729101-B1 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND PROADRENOMEDULLIN | BRAHMS GMBH (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20260069216-A1 | MULTIPLE PARTIALLY REDUNDANT BIOMETRIC SENSING DEVICES | POLTORAK TECH LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-12564615-B2 | Treatment method for cardiac hypertrophy | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-03 | — | — | US | claimed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4608432-A1 | EXTRACRANIAL METHODS FOR FACILITATING CEREBROSPINAL FLUID DRAINAGE | Institute for Basic Science (IBS) (KR) | 2025-09-03 | — | — | EP | claimed |
| EP-3809139-B1 | METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS | UNIV HEALTH NETWORK (CA) | 2025-08-20 | — | — | EP | claimed |
| US-12385926-B2 | MMP-8 as a marker for identifying infectious disease | B.R.A.H.M.S GMBH (DE) | 2025-08-12 | — | — | US | claimed |
| WO-2025133663-A1 | DIGITAL TISSUE REPAIR MODEL | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-06-26 | — | — | WO | claimed |
| US-20230194530-A1 | CIRCULATING CARDIOVASCULAR BIOMARKERS AND VASCULAR STABILIZING THERAPY | UNIVERSITY HEALTH NETWORK (CA) | 2023-06-22 | — | — | US | claimed |
| US-20230157264-A1 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | KYMAB LIMITED (GB) | 2023-05-25 | — | — | US | claimed |
| EP-4183867-A1 | METHOD FOR PRODUCING CARDIOMYOCYTE CELL MASS | Kaneka Corporation (JP) | 2023-05-24 | — | — | EP | claimed |
| US-11584792-B2 | Antibody therapies and methods for treating coronavirus infection | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-21 | — | — | US | claimed |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2023-01-26 | — | — | US | claimed |
| US-11523981-B2 | Cosmetic composition and its use, dermocosmetic formulation | LUXBIOTECH FARMACÊUTICA LTDA (BR) | 2022-12-13 | — | — | US | claimed |
| US-20220218701-A1 | COMPOSITIONS AND METHODS COMPRISING ENDOTHELIN A RECEPTOR ANTAGONISTS AND ANDROGEN THERAPIES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| CN-114468274-A | Application of traditional Chinese medicine composition in food for assisting in relieving hypertension, nutritional powder and preparation method of nutritional powder | 特康药业集团有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220144939-A1 | ANTIBODY THERAPIES AND METHODS FOR TREATING CORONAVIRUS INFECTION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-05-12 | — | — | US | claimed |
| WO-2022081792-A1 | ANTIBODY THERAPIES AND METHODS FOR TREATING CORONAVIRUS INFECTION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564615-B2 | Treatment method for cardiac hypertrophy | TNNT2, ADIPOR1, AGTR1 | KCNMA1 2909/4885KCNMB4 3329/4885RXFP1 713/4885 |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | KCNMA1 2678/4885KCNMB4 1714/4885RXFP1 1/4885 |
| US-20260069216-A1 | MULTIPLE PARTIALLY REDUNDANT BIOMETRIC SENSING DEVICES | VEGFA, KDR, TGFBR1 | KCNMA1 2229/4885KCNMB4 2025/4885RXFP1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.